JP6702967B2 - 二重特異性抗体のための精製プラットフォーム - Google Patents

二重特異性抗体のための精製プラットフォーム Download PDF

Info

Publication number
JP6702967B2
JP6702967B2 JP2017525320A JP2017525320A JP6702967B2 JP 6702967 B2 JP6702967 B2 JP 6702967B2 JP 2017525320 A JP2017525320 A JP 2017525320A JP 2017525320 A JP2017525320 A JP 2017525320A JP 6702967 B2 JP6702967 B2 JP 6702967B2
Authority
JP
Japan
Prior art keywords
protein
buffer
affinity matrix
affinity
heterodimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017525320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524740A (ja
JP2017524740A5 (enExample
Inventor
アンドリュー タスティアン
アンドリュー タスティアン
クリスティーヌ エンディコット
クリスティーヌ エンディコット
ベンジャミン アダムス
ベンジャミン アダムス
ジョン マッティラ
ジョン マッティラ
ハンネ バク
ハンネ バク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017524740A publication Critical patent/JP2017524740A/ja
Publication of JP2017524740A5 publication Critical patent/JP2017524740A5/ja
Application granted granted Critical
Publication of JP6702967B2 publication Critical patent/JP6702967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017525320A 2014-07-26 2015-07-24 二重特異性抗体のための精製プラットフォーム Active JP6702967B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
US62/029,463 2014-07-26
PCT/US2015/041936 WO2016018740A2 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Publications (3)

Publication Number Publication Date
JP2017524740A JP2017524740A (ja) 2017-08-31
JP2017524740A5 JP2017524740A5 (enExample) 2020-01-30
JP6702967B2 true JP6702967B2 (ja) 2020-06-03

Family

ID=53836215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525320A Active JP6702967B2 (ja) 2014-07-26 2015-07-24 二重特異性抗体のための精製プラットフォーム

Country Status (19)

Country Link
US (1) US10626142B2 (enExample)
EP (2) EP3172221B1 (enExample)
JP (1) JP6702967B2 (enExample)
KR (1) KR102440737B1 (enExample)
CN (1) CN107074906B (enExample)
AR (1) AR101262A1 (enExample)
AU (1) AU2015298156B2 (enExample)
DK (2) DK3172221T3 (enExample)
EA (1) EA036154B1 (enExample)
ES (2) ES2942533T3 (enExample)
FI (1) FI3912987T3 (enExample)
IL (1) IL255198B (enExample)
MX (1) MX377558B (enExample)
MY (1) MY187051A (enExample)
PL (2) PL3912987T3 (enExample)
SG (2) SG10201900661YA (enExample)
TW (1) TWI704155B (enExample)
WO (1) WO2016018740A2 (enExample)
ZA (1) ZA201700622B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN107614014B (zh) * 2015-05-28 2022-07-12 生物辐射实验室股份有限公司 亲和配体及其相关方法
CN108368166B (zh) * 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
HUE068564T2 (hu) * 2016-06-17 2025-01-28 Hoffmann La Roche Multispecifikus antitestek tisztítása
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MX2020003472A (es) 2017-11-01 2020-08-03 Chugai Pharmaceutical Co Ltd Variante e isoforma de anticuerpos con actividad biologica reducida.
EP3769083A1 (en) 2018-03-21 2021-01-27 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
CN112771379B (zh) * 2018-08-17 2024-07-02 瑞泽恩制药公司 用于测定多聚体蛋白质的量和纯度的方法和色谱系统
AU2019343053A1 (en) * 2018-09-21 2021-04-15 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
WO2020066270A1 (ja) * 2018-09-28 2020-04-02 株式会社カネカ κ鎖可変領域を含む抗体および／または抗体断片の製造方法
AU2019369421A1 (en) 2018-10-31 2021-06-03 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
MA55134A (fr) 2018-11-21 2021-09-29 Regeneron Pharma Anticorps anti-staphylococcus et leurs utilisations
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
MX2021015087A (es) * 2019-06-13 2022-01-18 Regeneron Pharma Metodos para eliminar componentes no deseados durante procesos cromatograficos de multiples etapas.
EP4524236A3 (en) 2019-12-06 2025-07-23 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
EP4141025A4 (en) * 2019-12-26 2024-04-24 ABL Bio, Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
KR102834449B1 (ko) 2019-12-27 2025-07-15 케이에스광학주식회사 투명한 방탄 적층 구조물
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
WO2022158889A1 (en) * 2021-01-25 2022-07-28 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
MX2024004764A (es) * 2021-10-19 2024-07-04 Alteogen Inc Procedimiento para purificar una proteína de fusión que tiene un dominio fc de igg.
KR20250028362A (ko) * 2022-06-22 2025-02-28 씨티바 바이오프로세스 알＆디 에이비 카파 경쇄-결합 대류 매트릭스
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN116769044A (zh) * 2023-07-11 2023-09-19 康日百奥生物科技(苏州)有限公司 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法
WO2025073922A1 (en) * 2023-10-04 2025-04-10 Sartorius Bia Separations D.O.O. Enhanced chromatographic separations of components in a mixture by employing chaotropic elution
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2025131519A1 (en) * 2023-12-21 2025-06-26 Cytiva Bioprocess R&D Ab Antibody separation with a vh3 binding separation matrix
WO2025173342A1 (ja) * 2024-02-13 2025-08-21 Jsr株式会社 Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2169299T3 (es) 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
US7825223B2 (en) * 2005-06-17 2010-11-02 Janssen Alzheimer Immunotherapy Methods of purifying anti A β antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
WO2010030222A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MY152963A (en) * 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JP6087054B2 (ja) * 2009-12-25 2017-03-01 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
PL2647707T3 (pl) * 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
JP6273219B2 (ja) * 2012-03-13 2018-01-31 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
EP3912987A1 (en) 2021-11-24
AR101262A1 (es) 2016-12-07
ES2942533T3 (es) 2023-06-02
KR102440737B1 (ko) 2022-09-06
US20160024147A1 (en) 2016-01-28
AU2015298156A1 (en) 2017-02-23
WO2016018740A8 (en) 2021-06-10
EP3172221A2 (en) 2017-05-31
SG10201900661YA (en) 2019-02-27
WO2016018740A3 (en) 2016-03-17
EP3912987B1 (en) 2023-03-22
EP3172221B1 (en) 2021-07-07
DK3172221T3 (da) 2021-08-09
KR20170035941A (ko) 2017-03-31
TW201617359A (zh) 2016-05-16
IL255198A0 (en) 2017-12-31
FI3912987T3 (fi) 2023-06-19
JP2017524740A (ja) 2017-08-31
US10626142B2 (en) 2020-04-21
IL255198B (en) 2022-04-01
DK3912987T3 (da) 2023-05-01
EA036154B1 (ru) 2020-10-06
TWI704155B (zh) 2020-09-11
SG11201700157VA (en) 2017-02-27
AU2015298156B2 (en) 2020-07-16
MY187051A (en) 2021-08-27
CN107074906B (zh) 2021-05-14
PL3912987T3 (pl) 2023-07-24
NZ728700A (en) 2023-09-29
EP3912987B9 (en) 2023-05-31
ES2881026T3 (es) 2021-11-26
PL3172221T3 (pl) 2021-12-27
WO2016018740A2 (en) 2016-02-04
BR112017001443A2 (pt) 2017-12-05
MX2017001217A (es) 2017-05-03
MX377558B (es) 2025-03-10
EA201790247A1 (ru) 2017-08-31
CN107074906A (zh) 2017-08-18
ZA201700622B (en) 2020-05-27
CA2955618A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP6702967B2 (ja) 二重特異性抗体のための精製プラットフォーム
JP2025102816A (ja) 多段階クロマトグラフィープロセス中の望ましくない成分を除去する方法
CN112771379A (zh) 用于测定多聚体蛋白质的量和纯度的方法和色谱系统
US12545702B2 (en) Methods for removing undesired components during multistage chromatographic processes
HK40062836B (en) Purification platform for bispecific antibodies
CA2955618C (en) Purification platform for bispecific antibodies
HK40062836A (en) Purification platform for bispecific antibodies
EA045004B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
HK1234069B (en) Purification platform for bispecific antibodies
EA049572B1 (ru) Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
NZ728700B2 (en) Purification platform for bispecific antibodies
BR112017001443B1 (pt) Método para fabricação de uma proteína
JP2025502157A (ja) アフィニティークロマトグラフィーを使用した不純物からのヘテロ二量体タンパク質の分離能を改善する方法
EA049692B1 (ru) Способы для улучшения отделения гетеродимерных белков от примесей с применением аффинной хроматографии
CN118871452A (zh) 用于改善使用亲和色谱法分离异源二聚体蛋白与杂质的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170509

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200507

R150 Certificate of patent or registration of utility model

Ref document number: 6702967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250